Actuate's Elraglusib Therapy Shows Encouraging Efficacy Against Advanced Salivary Gland Malignancies

Actuate Therapeutics unveiled Phase II trial data Monday demonstrating meaningful clinical benefit for elraglusib combined with carboplatin or cisplatin in treating advanced metastatic salivary gland cancers. The biotech company’s stock responded positively, gaining over 4% in pre-market trading following the announcement.

Trial Composition and Patient Demographics

The study population comprised 47% adenoid cystic carcinoma (ACC) patients alongside 53% non-ACC cases, capturing the heterogeneous nature of salivary gland malignancies. This balanced patient distribution strengthened the clinical relevance of findings across distinct cancer subtypes.

Overall Survival Data Demonstrates Durable Benefit

The median overall survival (OS) reached 18.6 months for the combined cohort, with survival curves showing 58% of patients alive at 12 months and 40% maintaining survival at 24 months. Among non-ACC patients specifically, median OS extended to 27.8 months—a notably longer duration suggesting differential therapeutic response by tumor histology.

Progression-Free Survival Performance

Median progression-free survival (PFS) measured 6.4 months, translating to 27% of enrolled patients remaining free from disease progression at one year. These metrics substantially exceeded historical benchmarks, which typically reported PFS of approximately 49 months for ACC and under 6 months for non-ACC cancers—indicating elraglusib’s potential advantage over conventional approaches.

Clinical Significance and Market Response

The comprehensive results earned publication in Clinical Cancer Research, establishing a peer-reviewed foundation for the therapy’s efficacy profile. Actuate shares closed Friday at $7.52, up 1.35%, before advancing further in pre-market activity, reflecting investor confidence in the program’s advancement toward potential commercialization.